References

Risdiplam in type 1 spinal muscular atrophy

10.1056/nejmoa2009965 · 2021 · External reference

Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases

10.1016/j.nmd.2018.01.003 · 2018 · External reference

Systematic review of presymptomatic treatment for spinal muscular atrophy

10.3390/ijns10030056 · 2024 · External reference

Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study

10.1186/s13023-018-0870-y · 2018 · External reference

Ten-year follow-up of monozygotic twin sisters with TSC-LAM: a rare case report

10.1016/j.rmcr.2026.102436 · 2026 · External reference

Risdiplam in presymptomatic spinal muscular atrophy

10.1056/nejmoa2410120 · 2025 · External reference

Exploring variability in cognitive functioning in patients with spinal muscular atrophy: a scoping review

10.1007/s10072-024-07503-x · 2024 · External reference

Epigenetic Insights into Tuberous Sclerosis Complex, Von Hippel-Lindau Syndrome, and Ataxia-Telangiectasia

10.3390/epigenomes9020020 · 2025 · External reference

A patient with both Charcot-Marie-Tooth disease (CMT 1A) and mild spinal muscular atrophy (SMA 3)

10.1016/j.nmd.2008.02.001 · 2008 · External reference

Spinal muscular atrophy

10.1016/j.ncl.2015.07.004 · 2015 · External reference

Phenotypic variability and mTOR pathway gene aberrations in familial tuberous sclerosis

10.1055/s-0037-1603349 · 2017 · External reference

A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy

10.1073/pnas.96.11.6307 · 1999 · External reference

Perfect match: mTOR inhibitors and Tuberous sclerosis complex

10.1186/s13023-022-02266-0 · 2022 · External reference

Emphasis on the importance of comprehensive clinical and genetic analysis – spinal muscular atrophy combined with phenylketonuria: a case report

10.1097/md.0000000000039076 · 2024 · External reference

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of Tuberous sclerosis complex

10.1093/neuonc/nov152 · 2015 · External reference

Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

10.1016/s1474-4422(22)00339-8 · 2022 · External reference

Severe brain involvement in 5q spinal muscular atrophy type 0

10.1002/ana.25549 · 2019 · External reference

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

10.1016/s1474-4422(21)00367-7 · 2022 · External reference

A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2

10.1093/hmg/8.7.1177 · 1999 · External reference

Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international Tuberous sclerosis complex consensus conference

10.1016/j.pediatrneurol.2013.08.001 · 2013 · External reference

Updated international Tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations

10.1016/j.pediatrneurol.2021.07.011 · 2021 · External reference

Central core myopathy with RYR1 mutation masks 5q spinal muscular atrophy

10.1016/j.ejpn.2010.04.003 · 2011 · External reference

Paradigm shift in the treatment of tuberous sclerosis: effectiveness of everolimus

10.1016/j.phrs.2023.106884 · 2023 · External reference

Autophagy in spinal muscular atrophy: from pathogenic mechanisms to therapeutic approaches

10.3389/fncel.2023.1307636 · 2024 · External reference

Safety of risdiplam in Japanese patients with spinal muscular atrophy: a 12-Month interim analysis of a postmarketing surveillance study

10.1007/s40120-025-00795-x · 2025 · External reference

Spinal muscular atrophy autophagy profile is tissue-dependent: differential regulation between muscle and motoneurons

10.1186/s40478-021-01223-5 · 2021 · External reference

Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review

10.1186/s13023-017-0671-8 · 2017 · External reference

Coinheritance of mutated SMN1 and MECP2 genes in a child with phenotypic features of spinal muscular atrophy (SMA) type II and Rett syndrome

10.1016/j.ejpn.2006.12.007 · 2007 · External reference

A novel TSC2 missense variant associated with a variable phenotype of Tuberous sclerosis complex: case report of a Chinese family

10.1186/s12881-018-0611-z · 2018 · External reference

Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next

10.1146/annurev-genom-102319-103602 · 2020 · External reference

TOR signaling in growth and metabolism

10.1016/j.cell.2006.01.016 · 2006 · External reference

Case report: whole-exome sequencing with MLPA revealed variants in two genes in a patient with combined manifestations of spinal muscular atrophy and Duchenne muscular dystrophy

10.3389/fgene.2021.605611 · 2021 · External reference

Prenatal phenotypical discrepancy in monozygotic twins with Tuberous sclerosis complex

10.1097/fm9.0000000000000109 · 2022 · External reference